Open Access

In vivo antitumor activity evaluation of cancer vaccines prepared by various antigen forms in a murine hepatocellular carcinoma model

  • Authors:
    • Chunfeng Si
    • Maolei Xu
    • Meiyu Lu
    • Yan Yu
    • Meizi Yang
    • Miaomiao Yan
    • Ling Zhou
    • Xiaoping Yang
  • View Affiliations

  • Published online on: October 11, 2017     https://doi.org/10.3892/ol.2017.7169
  • Pages:7391-7397
  • Copyright: © Si et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

0

Abstract

Cancer cell vaccines with strong specificity and low tolerance have been revealed to be a promising option for oncology treatment. Various antigen forms, including tumor cell lysate and glutaraldehyde‑fixed tumor cells, have been intensively used in cancer vaccine preparation. However, the most effective antigen form has not yet been identified. In the present study, the antitumor efficiency of vaccines prepared by these two antigen forms was systematically investigated. Murine H22 hepatocellular carcinoma cell lysate and glutaraldehyde‑fixed H22 hepatocellular carcinoma cells were conjugated with Freund's adjuvant to prepare vaccines, H22‑TCL and Fixed‑H22‑CELL, respectively. H22‑TCL and Fixed‑H22‑CELL were administrated by subcutaneous immunization in prophylactic and therapeutic strategies. The results of the present study revealed that H22‑TCL immunization induced more significant inhibition on tumor growth and metastasis compared with Fixed‑H22‑CELL injection. Furthermore, histopathological observation demonstrated that H22‑TCL vaccine induced larger areas of continuous necrosis within tumors compared to the Fixed‑H22‑CELL vaccine, which was associated with the extent of tumor inhibition. More importantly, the H22‑TCL vaccine injection elicited more evident antigen‑specific antibody responses compared with the Fixed‑H22‑CELL injection. Splenocytes from H22‑TCL vaccinated mice also exhibited a more significant T lymphocytes proliferation compared with that from Fixed‑H22‑CELL‑treated mice. All the results indicated that whole tumor cell lysate may be a more effective antigen form in cancer vaccine preparation compared with glutaraldehyde‑fixed tumor cells, which elicited more marked antigen specific humoral and cellular immune responses resulted with a superior antitumor efficiency. This would have important clinical signification for cancer vaccine preparation and serve a role in prompting this to other researchers.

Related Articles

Journal Cover

December 2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Si, C., Xu, M., Lu, M., Yu, Y., Yang, M., Yan, M. ... Yang, X. (2017). In vivo antitumor activity evaluation of cancer vaccines prepared by various antigen forms in a murine hepatocellular carcinoma model. Oncology Letters, 14, 7391-7397. https://doi.org/10.3892/ol.2017.7169
MLA
Si, C., Xu, M., Lu, M., Yu, Y., Yang, M., Yan, M., Zhou, L., Yang, X."In vivo antitumor activity evaluation of cancer vaccines prepared by various antigen forms in a murine hepatocellular carcinoma model". Oncology Letters 14.6 (2017): 7391-7397.
Chicago
Si, C., Xu, M., Lu, M., Yu, Y., Yang, M., Yan, M., Zhou, L., Yang, X."In vivo antitumor activity evaluation of cancer vaccines prepared by various antigen forms in a murine hepatocellular carcinoma model". Oncology Letters 14, no. 6 (2017): 7391-7397. https://doi.org/10.3892/ol.2017.7169